The earnings call highlighted significant progress in revenue growth, regulatory advancements for GEO-MVA, and successful fundraising efforts. However, challenges such as the termination of the BARDA contract, increased expenses, and delays in clinical trials were also noted.

Company Guidance

During the GeoVax Second Quarter 2025 Corporate Update Call, significant guidance was provided regarding the company's strategic path forward. The European Medicines Agency (EMA) granted an expedited development path for the GEO-MVA vaccine, allowing it to skip Phase I and II trials and proceed directly to a Phase III immunobridging trial, potentially accelerating its market authorization and revenue generation. The company also reported progress on its GEO-CMO4S1 COVID-19 vaccine, specifically targeting over 40 million immunocompromised adults in the U.S. and 400 million worldwide, with ongoing Phase II trials focusing on patients with blood cancers. Financially, GeoVax reported a net loss of $10.7 million for the first half of 2025, primarily due to increased R&D expenses of $10 million, driven by the BARDA contract and the Gedeptin and GEO-MVA programs. The company ended the second quarter with $3.1 million in cash but raised an additional $6 million in a follow-on public offering in July.

Revenue Increase

GeoVax reported revenues of $2.5 million for the first half of 2025, a significant increase from $301,000 in the same period in 2024, primarily due to the BARDA project NextGen contract.

EMA Guidance for GEO-MVA

GeoVax received guidance from the European Medicines Agency (EMA) for an expedited development path for its GEO-MVA vaccine, allowing the company to bypass Phase I and Phase II clinical trials.

Advancements in Vaccine Manufacturing

The advanced MVA manufacturing process is expected to provide a game-changing advantage in the production of MVA-based vaccines and therapies.

Expansion of Clinical Trials

GeoVax has expanded its clinical trials for GEO-CMO4S1, including a new site at the City of Hope facility for CLL patients.

Successful Fundraising

GeoVax concluded a follow-on public offering in July, raising almost $6 million in net proceeds, boosting its cash reserves.

GeoVax Labs (GOVX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

GOVX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	-0.25 / -	-0.91	―	―	―
Aug 06, 2025	2025 (Q2)	-0.35 / -0.35	-1.99	82.41% (+1.64)	―	―
May 01, 2025	2025 (Q1)	-0.66 / -0.45	-2.47	81.78% (+2.02)	―
Mar 27, 2025	2024 (Q4)	-0.80 / -0.88	-3.94	77.77% (+3.06)	―
Nov 12, 2024	2024 (Q3)	-1.32 / -0.91	-4.8	81.04% (+3.89)	―
Aug 06, 2024	2024 (Q2)	-3.37 / -1.99	-3.3	39.70% (+1.31)	―
May 14, 2024	2024 (Q1)	-5.56 / -2.47	-2.25	-9.78% (-0.22)	―
Feb 29, 2024	2023 (Q4)	-2.78 / -3.94	-2.1	-87.62% (-1.84)	―
Nov 08, 2023	2023 (Q3)	-3.04 / -4.80	-2.55	-88.24% (-2.25)	―
Aug 09, 2023	2023 (Q2)	-2.48 / -3.30	-2.7	-22.22% (-0.60)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

GOVX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$0.73	$0.66	-9.59%
May 01, 2025	$0.99	$1.01	+2.02%
Mar 27, 2025	$1.27	$1.11	-12.60%
Nov 12, 2024	$3.25	$2.70	-16.92%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does GeoVax Labs (GOVX) report earnings?

GeoVax Labs (GOVX) is schdueled to report earning on Nov 06, 2025, TBA (Confirmed).

What is GeoVax Labs (GOVX) earnings time?

GeoVax Labs (GOVX) earnings time is at Nov 06, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is GOVX EPS forecast?

GOVX EPS forecast for the fiscal quarter 2025 (Q3) is -0.25.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing